FDA.reportPublic FDA data

dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet

RxCUI
2122519
RxNorm name
dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet
Display name
dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet
Full name
dolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:39:02

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
DovatoDOLUTEGRAVIR SODIUM AND LAMIVUDINEViiV Healthcare Company68e45422-43ed-4cfb-9356-fae88d14a53a2025-10-29Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2122519

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
68e45422-43ed-4cfb-9356-fae88d14a53adolutegravir 50 MG / lamiVUDine 300 MG Oral Tablet [PSN] · dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [SCD] · dolutegravir 50 MG (equivalent to 52.6 MG dolutegravir sodium) / lamivudine 300 MG Oral Tablet [SY] · dolutegravir 50 MG / 3TC 300 MG Oral Tablet [SY]419These highlights do not include all the information needed to use DOVATO safely and effectively. See full prescribing information for DOVATO. DOVATO (dolutegravir and lamivudine) tablets, for oral use Initial U.S. Approval: 201920251029